Immunic Stock Z Score
| IMUX Stock | USD 1.24 0.01 0.81% |
Immunic | Z Score |
Immunic Company Z Score Analysis
Immunic's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Immunic Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunic is extremely important. It helps to project a fair market value of Immunic Stock properly, considering its historical fundamentals such as Z Score. Since Immunic's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunic's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunic's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
According to the company's disclosures, Immunic has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Immunic Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunic from analyzing Immunic's financial statements. These drivers represent accounts that assess Immunic's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunic's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 74.9M | 239.5M | 226.4M | 44.5M | 51.2M | 48.7M | |
| Enterprise Value | 46.1M | 112.7M | 140.1M | (60.6M) | (69.7M) | (66.2M) |
Immunic Institutional Holders
Institutional Holdings refers to the ownership stake in Immunic that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunic's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunic's value.| Shares | Sierra Summit Advisors Llc | 2023-12-31 | 324.8 K | Cowen And Company, Llc | 2023-12-31 | 317.1 K | Soleus Capital Management, L.p. | 2023-12-31 | 300 K | Innovis Asset Management Llc | 2023-09-30 | 272.5 K | Schonfeld Strategic Advisors Llc | 2023-09-30 | 238.7 K | Northern Trust Corp | 2023-12-31 | 164.4 K | Two Sigma Advisers, Llc | 2023-12-31 | 147.4 K | State Street Corporation | 2023-12-31 | 125.8 K | Two Sigma Investments Llc | 2023-12-31 | 116.5 K | Rtw Investments, Llc | 2023-12-31 | 4.3 M | Gratus Capital Llc | 2023-12-31 | 1.9 M |
Immunic Fundamentals
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.68 | ||||
| Current Valuation | 66.17 M | ||||
| Shares Outstanding | 89.93 M | ||||
| Shares Owned By Insiders | 7.72 % | ||||
| Shares Owned By Institutions | 58.08 % | ||||
| Number Of Shares Shorted | 3.03 M | ||||
| Price To Earning | (6.65) X | ||||
| Price To Book | 4.48 X | ||||
| EBITDA | (99.11 M) | ||||
| Net Income | (93.61 M) | ||||
| Cash And Equivalents | 72.77 M | ||||
| Cash Per Share | 1.85 X | ||||
| Total Debt | 1.33 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 0.64 X | ||||
| Cash Flow From Operations | (70.83 M) | ||||
| Short Ratio | 5.23 X | ||||
| Earnings Per Share | (2.11) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 11.5 | ||||
| Number Of Employees | 77 | ||||
| Beta | 1.95 | ||||
| Market Capitalization | 111.51 M | ||||
| Total Asset | 54.3 M | ||||
| Retained Earnings | (410.89 M) | ||||
| Working Capital | 27.8 M | ||||
| Current Asset | 32.33 M | ||||
| Current Liabilities | 4.73 M | ||||
| Net Asset | 54.3 M |
About Immunic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Immunic Piotroski F Score and Immunic Valuation analysis. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Immunic Stock analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.68) | Return On Equity (1.31) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.